Last week we witnessed a fresh bullish momentum as the Infosys stock price broke out of a symmetrical triangle pattern, signaling a continuation of the uptrend. Traders can buy for a target of Rs 2100 ...

A global commission of experts has called for a radical shift in how obesity is diagnosed, with less reliance on body mass index (BMI) to define disease. The commission, published in Lancet Diabetes ...

People are being “overdiagnosed” with obesity, leading medics have warned as they called for a “reframing” of the way the condition is diagnosed. Academics have suggested that a body mass ...

Longer duration phase 3 trials will enable comprehensive evaluation of efficacy and tolerability of this potential pharmacotherapeutic for the treatment of obesity." 4) LLY Stock Is Forming a Daily ...

SUI was trading within a symmetrical triangle pattern, with a key support level to provide a potential base for upward momentum. A slight dip remains possible as the coin sought stronger support ...

To make up for looming revenue gaps, Roop said Big Pharma will increasingly turn to M&A next year, buying smaller biotechs developing drugs in major markets such as obesity and oncology.

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.